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Introduction 
To understand the causes and consequences of mental disorders, it is essential to measure the 
frequency of these disorders in the general community.  Mapping the epidemiological landscape is 
the basis upon which researchers can develop hypotheses related to causal mechanisms – for 
example why is schizophrenia more common in men than women (Aleman et al., 2003), in some 
migrant groups (McGrath et al., 2004, Cantor-Graae and Selten, 2005), and why does the incidence 
and prevalence vary between sites (McGrath, 2006, Saha et al., 2006)? However, from a policy and 
planning perspective, the research questions tend to more pragmatic and user-focused. Are those 
with serious mental disorders accessing services and are they receiving an optimal mix of services? 
Do people who use services have better outcomes? Are there unmet needs that can be better 
addressed? In order to address these issues, high quality epidemiologically-informed research is 
required.  
In order to distribute the limited health dollar effectively, governments need to understand the 
causes and distribution of health loss, both in terms of premature mortality and disability. This has 
been brought into sharp focus in recent years with influential research initiatives, such as the Global 
Burden of Disease Studies, which synthesize epidemiological data from around the world to produce 
directly comparable estimates of health loss due to a large number of diseases and injuries using 
standardized metrics (Murray et al., 2012). The core standardized metric of burden of disease is the 
disability-adjusted life year (DALY) which is the sum of years of life lost (YLL) and years lived with 
disability (YLD). Estimates for each metric are age-, sex-, disease-, and country-specific. As a result of 
this work, there is now robust evidence to show how mental disorders contribute substantially to 
global burden of disease (Whiteford et al., 2015, Whiteford et al., 2013).   
Despite the strengths of such research, it is important to recognize that accurate estimates rely on 
the availability of high-quality epidemiological data. Large research collaborations such as the World 
Mental Health Survey and Global Burden of Disease Studies have successfully increased awareness 
amongst Governments and research institutions around the world of the need for regular 
epidemiological data collection to chart the health of nations. With respect to the US, there is a rich 
tradition of regular surveys of substance use (National Survey on Drug Use and Health (Substance 
Abuse and Mental Health Services Administration (SAMHSA), 2016) and for several years an 
associated National Survey on Drug Use and Health-Mental Health Surveillance Study (Substance 
Abuse and Mental Health Services Administration (SAMHSA), 2014). International consortia have 
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been developed in order to combine outputs from studies for transnational analyses (Kessler and 
Ustun, 2008). Indeed, psychiatric epidemiology can be justly proud of its achievements over the last 
few decades.  
In the most recent Global Burden of Disease Study (GBD 2013), over 300 studies met inclusion 
criteria and reported estimates for the prevalence of mental disorders (see Table 1). The inclusion 
criteria included the requirement that case definitions met DSM or ICD diagnostic criteria, and 
sampling was representative of the general population. GBD 2013 identified 30 studies from 20 
different countries that provided data on the prevalence of bipolar disorder, and 48 studies from 21 
different countries that provided data on the prevalence of schizophrenia and related disorders. 
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Table 1: Data sources from GBD 2013 
Disorder Parameter No of studies No of countries 
Depressive disorders Prevalence 125 51 
 Incidence 5 3 
 Remission 2 1 
 Mortality 10 7 
Anxiety disorders Prevalence 79 45 
 Incidence - - 
 Remission 5 4 
 Mortality - - 
Schizophrenia Prevalence 48 21 
 Incidence 32 13 
 Remission 18 17 
 Mortality 34 21 
Bipolar disorder Prevalence 30 20 
 Incidence - - 
 Remission - - 
 Mortality 5 5 
Eating disorders Prevalence 31 19 
 Incidence 6 5 
 Remission 9 6 
 Mortality 8 5 
Conduct disorder and ADHD Prevalence 61 27 
 Incidence 3 3 
 Remission 13 4 
 Mortality - - 
Autism and Asperger’s disorder Prevalence 28 15 
 Incidence 4 3 
 Remission 4 3 
 Mortality 3 3 
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However, the availability and accuracy of data varies across the spectrum of mental disorders. A 
particular challenge for low prevalence psychotic disorders is sample size.  For low prevalence 
disorders, many well individuals will need to be screened and assessed in order to identify a 
sufficient number of cases required for epidemiological purposes. Statistically, this creates inherent 
difficulties in generating reliable prevalence estimates within reasonable bounds of uncertainty.  Yet, 
it is typically these low prevalence mental disorders which, as a group, are most disabling and most 
likely to use services. For example, whilst schizophrenia is a relatively low prevalence disorder (1-3% 
projected lifetime risk (Saha et al., 2006), it ranked 12th globally in terms of years lived with 
disability (YLDs) amongst the 291 diseases and injuries in GBD 2013 (Institute for Health Metrics and 
Evaluation., 2013). The ranking is largely a function of this disorder typically emerging in young 
adults, often having a persistent or recurrent course of illness and having a high disability. In fact the 
acute phase of schizophrenia has the highest disability of all 291 diseases and injuries in GBD 2013 
(Salomon et al., 2015).  
This report will address selected topics related to epidemiological data collection of psychotic 
disorders, with a focus on the advantages and challenges of different study designs and data 
collection methods. The report is based on narrative reviews and expert opinions; however the 
authors have been involved in extensive data collection including major systematic reviews and 
meta-analyses of the incidence, prevalence and outcomes (i.e. recovery and mortality) of psychotic 
disorders.  
What to measure – frequency estimates 
A range of frequency measures are available to help create a comprehensive epidemiological profile 
of disease. Measures such as prevalence, incidence, mortality and remission are inter-related and it 
is important to understand their relationship for any particular disease in a population. Saha and 
colleagues have applied this model to schizophrenia (Saha et al., 2008). 
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Figure 1: Generic disease model 
General population
Deaths in the general 
population from causes other 
than disease X 
Existing cases of disease X 
(prevalence)
Deaths attributable to disease 
X (cause-specific mortality)
New cases of disease X 
(incidence)
Cases recovered from 
disease X (remisson)
Deaths in people with disease X 
attributable to other causes
 
Central to the generic disease model in Figure 1 is the pool of cases of a disease, referred to as 
prevalent cases, and usually expressed as a ratio or proportion of a given population (for example 5 
cases in a population of 1000 would a prevalence of 0.5). It is common to have a time specifier 
attached to prevalence estimates to provide context and meaning. Prevalence in the model is the 
proportion of individuals who currently have the disorder, or have had it in the past month (‘point’ 
prevalence). Sometimes we may wish to know what proportion of the population has had the 
disorder at any time in their life (‘lifetime’ prevalence).   
The number of prevalent cases at any time is influenced by the proportion of a given population that 
develops a disorder during a given period of time, measured as incidence. This metric has a 
numerator (count of new cases), a denominator (the count of the risk set or background population, 
which included the new cases), and a time reference (usually per annum). In order to better capture 
the impact of different population age structures on incidence metrics, incidence rates can also be 
expressed in person-time (e.g. 6 cases in a population of individuals with 100 person-years).  
The number of prevalent cases at any time is also influenced by the cases which leave the pool of 
prevalent cases. This either happens as a result of recovery from a disease (remission) or death 
(either from the disease or another cause). Remitted cases may, of course, reenter the prevalent 
case pool at times of relapse and in reality there will be a proportion of cases which are in a state of 
flux between the two pools. Deriving prevalence estimates from those in contact with services, 
brings a potential bias of underestimating the true prevalence and assuming the characteristics of 
those with a disorder is the same as those accessing services (who may be a more severe or 
persistent subgroup). While risk factor epidemiology prefers estimates from representative samples 
(e.g. sites with comprehensive case registers can derive frequency metrics from population-based 
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birth cohorts), observational studies that focus on service access and unmet need may be able to 
accommodate more relaxed sampling strategies.  
Mortality also depletes the number of prevalent cases in the model and premature mortality 
depletes the prevalent population more quickly. There is a particular focus on the increased risk of 
premature mortality in those with psychotic disorders (Suetani et al., 2015, Walker et al., 2015) 
which can be described by standardized mortality ratios (SMRs), calculated by dividing the observed 
mortality rates in a given population (e.g. the number of deaths in a group of individuals with 
schizophrenia) by the expected mortality rates in that same group as predicted by age- and sex-
specific mortality rates for a standard population. Thus, an SMR of 2.0 would indicate that people 
with schizophrenia are twice as likely to die compared with the general population during a given 
time period. The SMRs can be calculated for overall mortality (all-cause) or for more specific, widely 
used categories (e.g. cancer, cardiovascular disease, endocrine disorders or suicide). 
As shown in Table 1, the overwhelming majority of epidemiological studies have focused on 
reporting estimates of mental disorder prevalence. The likely reason is that it is generally more 
straight-forward and less resource intensive to conduct a cross-sectional population-based 
prevalence survey. Incidence studies of low prevalence disorder require very large catchment areas 
and/or prolonged recruitment windows in order to accumulate sufficient cases to derive reliable 
estimates. Studies related to recovery or mortality require record linkage or prospective longitudinal 
research design. Prevalence itself is a product of the interplay of incidence, remission and mortality 
and the strategies for reducing prevalence are those that reduce incidence and mortality, and/or 
increase remission. 
 
What to measure - disability and functional impairment 
Both psychosis and bipolar disorder are known to carry substantial disability and impairment. GBD 
disability weights rank acute schizophrenia as the most disabling disease state of all GBD causes 
(Salomon et al., 2015). In the NCS-R study in the US, bipolar disorder had the highest percentage of 
severe cases (82.9%) among mood disorders (Kessler et al., 2005). This fact, combined with the low 
remission rates seen in these disorders could perhaps rationalise a case for shifting our 
understanding of meaningful positive mental health outcomes away from untenable reductions in 
prevalence to reductions in disorder severity and associated functional impairment. 
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Both the Short Form-12 (SF-12) and Sheehan disability scale (SDS) are instruments which have been 
used to quantify mental disorder severity (or more accurately the functional impairment it causes). 
They are quick to conduct and can be used independently or as add-on modules to other surveys. 
Reducing disability is arguably the target that would result in the most impact on improving health 
outcomes for the most severe mental disorders such as psychosis and bipolar disorder given the 
limited capacity of current interventions to reduce incidence and increase remission rates.  
Disability as measured by these instruments will persist for most individuals with psychosis and 
bipolar disorder, even with optimal clinical treatment. It is important therefore to collect 
information on engagement with services, usually provided through non-government agencies that 
promote social inclusion and enhance personal recovery and quality of life.  
 
Epidemiological studies from the US 
As mentioned previously, the Global Burden of Disease Study models health estimates by drawing 
upon available epidemiological data and Table 2 shows the US epidemiological studies for 
schizophrenia and bipolar disorder which met GBD inclusion criteria. Two nationally representative 
prevalence surveys have been conducted in the US adult population. These are large studies 
capturing prevalence estimates of a range of mental disorders. The first, the Epidemiological 
Catchment Area Survey (ECA), conducted in 1989, used DSM-III diagnostic criteria and reported age-, 
sex- and race-specific, one-month prevalence estimates for schizophrenic disorders (0.7%), 
schizophrenia (0.6%) and schizophreniform disorders (0.1%) (Regier et al., 1993, Leaf et al., 1991). 
The ECA also reported one-month prevalence estimates for bipolar disorder (0.8% (SE=0.2)) 
(Weissman et al., 1988). 
The second was the National Comorbidity Survey Replication (NCS-R) conducted in 2001-2003 
(Kessler et al., 2005, Gum et al., 2009), and was preceded by the original National Comorbidity 
Survey (NCS) conducted in 1990-1992 (Kessler et al., 1994). The NCS-R reports an age-standardised 
bipolar disorder (I and II) prevalence of 2.6% (SE=0.2). Schizophrenia and other non-affective 
psychoses were not included in the NCS-R due to challenges discussed later in this report.  
In addition to these two large national surveys, Table 2 shows several other studies held in the GBD 
datasets. These studies are smaller and less representative studies and/or report epidemiological 
parameter estimates other than prevalence. From Table 1 we can see that data sources for 
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schizophrenia are dominated by prevalence studies to a lesser extent than for other disorders. In 
fact, the ECA is the only population-based survey meeting GBD inclusion criteria reporting the 
prevalence of schizophrenia in the US. Additionally, with the exception of the NCS-R, the studies 
found in Table 2 are relatively old with data collection generally taking place well over 20 years ago.  
11 
 
Table 2: GBD data sources for USA for schizophrenia and bipolar disorder 
Study Year Representativeness Measure Study design 
Schizophrenia 
Regier DA, Farmer ME, Rae DS, et al. One-month prevalence of mental 
disorders in the United States and sociodemographic characteristics: the 
Epidemiologic Catchment Area study. Acta Psychiatrica Scandinavica 1993; 
88(1): 35-47. 
1980 National (ECA 
Study) 
Prevalence Cross-sectional survey 
(general population) 
Auslander LA, Jeste DV. Sustained remission of schizophrenia among 
community-dwelling older outpatients. Am J Psychiatry. 2004; 161(8): 1490-3. 
1990 National Remission Longitudinal cohort study 
(clinical sample) 
Bresnahan MA, Brown AS, Schaefer CA, Begg MD, Wyatt RJ, Susser ES. 
Incidence and cumulative risk of treated schizophrenia in the prenatal 
determinants of schizophrenia study. Schizophr Bull. 2000; 26(2): 297. 
1959 California Incidence Longitudinal birth cohort 
study (general population) 
Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev 
K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra 
S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, 
Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-
year international follow-up study.Br J Psychiatry. 2001; 178: 506-17. 
1978 Hawaii Remission Longitudinal cohort study 
(clinical sample) 
Martin RL, Cloninger CR, Guze SB, Clayton PJ. Mortality in a follow-up of 500 
psychiatric outpatients. I. Total mortality. Arch Gen Psychiatry. 1985; 42(1): 
47-54. 
1967 Missouri Standardised 
mortality 
ratio 
Longitudinal cohort study 
(clinical sample) 
Bipolar disorder 
Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML, Florio LP. 
Affective disorders in five United States communities. Psychol Med. 1988; 
18(1): 141-53 
1980 National (ECA Study Prevalence Cross-sectional survey 
(general population) 
Kessler RC, Chiu W, Demler O, Walters EE. Prevalence, severity, and 2001 National (NCS-R Prevalence Cross-sectional survey 
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comorbidity of 12-month DSM-IV disorders in the national comorbidity survey 
replication. Archives of General Psychiatry 2005; 62(6): 617-27. 
Study) (general population) 
Gum AM, King-Kallimanis B, Kohn R. Prevalence of mood, anxiety, and 
substance-abuse disorders for older Americans in the national comorbidity 
survey-replication. Am J Geriatr Psychiatry. 2009; 17(9): 769-81. 
2001 National (NCS-R 
Study) 
Prevalence Cross-sectional survey 
(general population, older 
adults) 
Black DW, Winokur G, Nasrallah A. Mortality in patients with primary unipolar 
depression, secondary unipolar depression, and bipolar affective disorder: a 
comparison with general population mortality. Int J Psychiatry Med. 1987; 
17(4): 351-60 
1970 Iowa Standardised 
mortality 
ratio 
Longitudinal cohort study 
(clinical sample with record 
linkage) 
Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrews JA. Adolescent 
psychopathology: I. Prevalence and incidence of depression and other DSM-
III-R disorders in high school students. J Abnorm Psychol. 1993; 102(1): 133-
44. 
1987 West Central, 
Oregon 
Prevalence 
and 
incidence 
Longitudinal cohort study 
(general population) 
Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample 
of older adolescents: prevalence, phenomenology, comorbidity, and course. J 
Am Acad Child Adolesc Psychiatry. 1995; 34(4): 454-63. 
1987 West Central, 
Oregon 
Prevalence 
and 
incidence 
Longitudinal cohort study 
(general population) 
Costello EJ. Child psychiatric disorders and their correlates: a primary care 
pediatric sample. J Am Acad Child Adolesc Psychiatry. 1989; 28(6): 851-5. 
1984 Pittsburgh, 
Pennsylvania 
Prevalence Cross-sectional survey 
(clinical sample) 
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How to measure 
In the previous section we discussed the very limited national estimates of psychotic and bipolar 
disorder prevalence. In this section we will explore the advantages and disadvantages of a range of 
study designs and data sources which can be utilised in psychiatric epidemiology. We will begin with 
potential study designs and data sources for ascertaining prevalence.  
Cross-sectional surveys  
Cross-sectional surveys are the most commonly used study design in ascertaining prevalence, 
providing a snapshot in time of population mental health status. Although specific skills are required 
(e.g. sampling techniques for a representative sample), study design and data analysis are arguably 
more straightforward than most other study designs used in psychiatric epidemiology. For example, 
these study designs require no follow-up and thus are more efficient to conduct than longitudinal 
study designs.  
Several well validated instruments are available for the assessment of a range of mental disorders. 
These include the Composite International Diagnostic Interview (Kessler and Ustun, 2004), the 
Structured Clinical Interview for DSM-IV (First et al., 2001), the Schedule for Clinical Assessment in 
Neuropsychiatry (Wing et al., 1990) , and the Mini-International Neuropsychiatric Interview 
(Sheehan et al., 1998). A significant advantage of a number of instruments is that they are designed 
to be administered by trained lay-interviewers allowing for rapid surveying of large samples. 
However, these instruments are designed for the screening for a range of disorders (especially 
common mental disorders), and less suited for the confirmation of one particular group of disorders 
(such as psychotic disorders). In response to this issue, the Diagnostic Interview for Psychosis (DIP) 
was developed (Castle et al., 2006) . The DIP contains interview questions and probes, including 
items from the WHO Schedules for Clinical Assessment in Neuropsychiatry (Wing et al., 1990) 
mapped onto the 90 diagnostic items of the Operational Criteria Checklist for Psychotic and Affective 
Illness (OPCRIT) (McGuffin et al., 1991) A computer algorithm provides diagnostic classification in 
accordance with ICD-10 and DSM-IV criteria on the basis of the DIP ratings, thus reducing subjective 
bias in the interpretation of symptoms and signs.  
There are some drawbacks to cross-sectional study designs (they often need to be large and can be 
expensive); however, two major challenges in using this study design are specifically inherent to the 
nature of psychosis and bipolar disorder. Some studies have elected to exclude non-affective 
psychoses because previous studies have shown lay-administered interviews over-estimate 
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prevalence (e.g. NCS-R) (Kessler, 2005). While originally thought of as an epidemiological nuisance, it 
is now widely appreciated that many otherwise well individuals in the community report 
experiencing isolated psychotic experiences (e.g. lifetime prevalence = 5.8%) (McGrath et al., 2015a). 
The second significant challenge for population-based surveys of low prevalence disorders, such as 
psychosis, is that very large sample sizes (in the thousands) are required to detect enough cases for 
results to be meaningful. Both of these issues are major barriers to traditional population-based 
cross-sectional survey designs and are likely the reason for the dearth of reliable and recent 
prevalence estimates shown in Table 2. 
Administrative data 
Another method to ascertain disorder prevalence is to draw upon administrative data.  A popular 
source of administrative data is from health service/patient records – sometimes referred to as 
‘treated’ prevalence as presumably all cases from such a dataset have undergone some form of 
treatment (optimal or otherwise). The advantage is that this data is routinely recorded and readily 
available at relatively low cost. A clear disadvantage of this method is that people who have not 
come into contact with a health service will not be captured, thereby underestimating the true 
population prevalence of a disorder. The argument may be made that this has less implications for 
severe disorders such as psychosis in high income countries where the likelihood of someone being 
in contact with a health service at some point in time is fairly high; however, much of this depends 
on other factors such as accessibility to publicly funded health services. Generally speaking, treated 
prevalence estimates are not considered representative of the general population are excluded from 
GBD mental disorder datasets. For service planning, it is especially important to assess unmet need, 
thus those who have not made contact with treatment setting will be missed.  
Another type of administrative data relates to insurance databases. As with hospital datasets, these 
datasets underestimate prevalence in the general population; however, it is an accessible and rich 
data source which can be informative if its limitations are acknowledged and accounted for in 
epidemiological research. One way in which to do this is to create a crosswalk between 
administrative data and data obtained from the general population (data from both sources are 
required) which makes upwards corrections to data from ‘suboptimal’ sources. Inbuilt covariates 
within meta-regression methods are commonly used and this is the basic process employed in 
creating epidemiological models in GBD. 
Another form of administrative data is from health registries (typically state or national level). These 
store detailed data on people with a specific disease or condition and known registries exist for 
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some mental disorders.  Again, this data is readily available but is likely to be incomplete. The 
comprehensiveness of these registries varies enormously from country to country; however some 
countries (such as those in Scandinavia) are known to have registries for schizophrenia of sufficient 
quality that they provide data which can be considered reliable enough to approximate true 
population prevalence. However, the available data from US population surveys suggest that 
approximately 40% of individuals  with schizophrenia are not in contact with services  for extended 
periods even while experiencing significant symptoms (Mojtabai et al., 2009). 
What other options are available?  
Earlier we noted that disease prevalence is a function of the other epidemiological parameters 
(incidence, remission and mortality). Prevalence holds important information about the status of 
population mental health but, when viewed on its own, it provides little opportunity to improve 
mental health. However, key metrics related to mortality and remission can be used to explore and 
complement prevalence estimates (Saha et al., 2008). 
Record linkage  
While outside the scope of this report, the mortality associated with psychosis has received 
considerable attention in recent years (Saha et al., 2007, Olfson et al., 2015). Excess mortality in 
those with psychosis and bipolar disorder, largely due to comorbid conditions, is well-documented 
and of particular interest because it offers real opportunities for improving health outcomes (the 
issue of physical comorbidity is discussed later in the report). Record linkage studies (e.g. between 
treatment services and/or national death registers) are also regularly utilized to provide an index of 
mortality associated with mental disorders (Mortality and Causes of Death, 2015, Olfson et al., 2015, 
Walker et al., 2015). National registers of death can be linked to other administrative data, such as 
hospital records, in order to calculate the standardized mortality ratio (SMR), which compares 
mortality in people with schizophrenia vs the general population. Opportunities for data linkage 
often arise after data collection and study completion, thus seeking consent for future unspecified 
(but ethically approved) studies is prudent.  
Longitudinal research  
From Table 1 we can see that longitudinal cohort study designs are regularly employed in psychiatric 
epidemiology. Drawing a cohort from a population without the disorder permits the estimation of 
incidence (hence a general population sample); whilst drawing on a population with the disorder 
provides the opportunity to study remission (hence a clinical sample). Typically, these studies are 
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prospective in nature but, in the presence of high quality administrative data, retrospective designs 
are also feasible. Prospective studies are necessarily lengthy and can be costly. However, 
longitudinal research also provides opportunities for other relevant health outcomes to be assessed 
using repeated measures. For example, prevalent samples based on administrative settings can seek 
permission for follow-up assessment of the entire sample or a selected subsample (i.e. build a ‘panel 
study’), and/or record linkage (e.g. with insurance agencies, national death registers etc). The focus 
on early psychosis services in many nations now allow for the opportunity to build incidence-like 
cohorts for follow up.   
Access to patients via smart phones and other internet related devices is an area of enormous 
growth currently and this disruptive technology will influence the design of future epidemiological 
studies (Aanensen et al., 2014, Palmier-Claus et al., 2012, Kimhy et al., 2012). For example, 
subgroups of respondents that have access to this technology can be drawn from samples collected 
via traditional epidemiological studies for repeated-measure assessments of symptoms, service use, 
compliance, unmet need etc. These smaller follow-up studies can be very cost-effective and as this 
technology becomes more widely available, it will probably be a preferred mode of data collection 
for many individuals with psychosis.  
 
An issue of ‘caseness’ 
In order to count the disorders of interest, it is essential to have reliable diagnostic criteria to define 
caseness.  More than any other disorder, commentators seem to be constantly drawn to debates 
related to the label schizophrenia. What is it? Should we abandon the name? Would a fresh label 
reduce stigma? Medicine has many poorly understood syndromes that are known to be 
heterogeneous. While we wait for the inevitable progress of science, we are forced to make do with 
interim labels. These diagnostic categories can be reliability measured, despite psychometric 
weaknesses related to validity, and can guide treatment and allow broad predictions about 
prognosis.  The fact that these debates attract so much attention on a regular basis speaks to the 
sense of frustration clinicians (and the general population) have with schizophrenia – it is a very 
disabling and poorly understood group of disorders. Even our best treatments are suboptimal, thus 
residual stigma is hard to address from community education alone. There is a long and well-
rehearsed debate about moving from categorical to dimensional measures of psychosis (Van Os et 
al., 1999, Potuzak et al., 2012). In more recent years, this has evolved in a call for a shift from the use 
of unreliable diagnostic criteria during the early phases of psychotic disorders to the use of a 
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‘staging’ model. (Scott et al., 2013). This model acknowledges that the early phases of psychosis are 
‘pleuripotent’, and that clinical and service needs are better captured by the purposeful use of 
interim stage-related classifications (Fusar-Poli et al., 2014). Future epidemiological studies should 
endeavor to incorporate these concepts, as it will be important to explore if these concepts can be 
conceptualized within an epidemiological framework.  
Common mental disorders such as major depression or generalized anxiety disorders lend 
themselves to structured questionnaires that can be delivered by well-trained lay interviewers 
(Kessler and Üstün, 2008, Heeringa et al., 2008). The core features are understood by the general 
community as anxiety and depression can be conceptualized on a continuum, and mild and/or 
transient anxiety or depression is universal. In contrast, the symptoms and signs of psychotic 
disorders are less precise and usually require clinical judgment. The elements that underlie 
diagnostic criteria cannot be readily operationalized. When is a delusion an overvalued belief? What 
is a hallucination in the context of a psychotic disorder versus a culturally-understandable event (e.g. 
transient hallucinations associated with bereavement)?  
There has been a shift in our understanding of how to define psychosis in recent years. This has been 
driven by pragmatic concerns (e.g. the cost of undertaking detailed clinically-informed diagnostic 
instruments) versus the realization that sometimes ‘less is more’. Sometimes called ‘shallow 
phenotyping’, there is awareness that simple and imprecise measure of a health outcome can be 
sufficient for many research questions. For example, asking a simple question such as “Has a doctor 
ever told you that you have schizophrenia or a psychotic disorder?” may be suitable for 
concentrating putative cases for two-stage studies.  In the past, exhaustive diagnostic interview have 
been blended with detailed chart reviews and consensus criteria. However, for pragmatic as well as 
scientific reasons, these time consuming procedures are not suitable for large scale epidemiological 
surveys.  
Future proofing for changes in diagnostic criteria 
Changes in diagnostic criteria over time have the potential to significantly influence epidemiological 
research. There may be changes in the instrumentation that is used for data collection and the 
estimates themselves may increase or decrease. This also has implications for drawing comparisons 
in estimates and particularly for longitudinal research where data from different time points may 
have used different diagnostic criteria. While some changes are terminological, for example 
Schizophrenia and Other Psychotic Disorders in DSM-IV to Schizophrenia Spectrum and Other 
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Psychotic Disorders in DSM-5, others add new disorders, for example the move to include 
Schizotypal (Personality) Disorder from the Personality Disorders chapter. 
When changes are made to the diagnostic criteria, the threshold for a case can change. For example, 
In DSM-5, changes have been made to criterion A for schizophrenia with bizarre delusions and 
Schneiderian auditory hallucinations have been removed due to poor reliability in differentiating 
bizarre delusions from non-bizarre delusions and the non-specificity of Schneiderian symptoms. In 
DSM-5, two Criterion A symptoms are now required for the diagnosis of Schizophrenia (only one was 
required in DSM-IV) and in addition to Criterion A symptoms, one additional core positive symptom 
must be present (i.e. a delusion, hallucination, or disorganized speech).  Additionally, the diagnostic 
criteria no longer identify subtypes and a dimensional criterion (measured on a 0–4 point scale) to 
evaluate severity in Schizophrenia is included in Section III. The implications from changes that raise 
the threshold needed for a diagnosis is that the number of individuals who meet case definition in a 
survey might fall but in reality it is unlikely the change will significantly alter demand for psychosis 
services (though it may decrease the use of antipsychotic medication and this could better align 
clinical need and pharmacological treatment). 
The United States is a culturally diverse country and Western concepts of mental disorder and the 
way symptoms of a disorder are expressed can vary between cultures. One US study has shown that 
differences exist in response to questions in the Composite International Diagnostic Interview 
concerning depression but these do not account for relatively low-prevalence of depression among 
minority groups (Breslau J. et al., 2008). These issues are even more pronounced in psychosis 
research if the category of observation shifts from diagnostic criteria to the level of symptom. Large 
cross-national studies of hallucinations and delusions confirm prior expectations that cultural factors 
influence the frequency, age of onset and nature of psychotic experiences (McGrath et al., 2016, 
McGrath et al., 2015b, Nuevo et al., 2010).   
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The epidemiology of psychosis; selected examples from recent literature  
Finland  
One of the most impressive studies in recent decades has come from Finland (Perala et al., 2007). A 
representative sample (n = 8028) of those aged 30 year or older were screened for psychotic 
disorder and bipolar disorder (with the Composite International Diagnostic Interview (CIDI)), and 
with cross-linking with various national registers (hospital discharge records, disability pensions 
records, and pharmacoepidemiology registers). Screen-positive individuals were then screened with 
the Structured Clinical Interview for DSM-IV (SCID) (First et al., 2001). Of the various methods used 
to screen for cases used in this study, the national hospital discharge register was the most reliable 
(kappa = 0.8).  
Australia 
The Australian Federal Government commissioned two studies to determine the prevalence and 
correlates of psychotic disorder. The Low Prevalence Survey of Psychotic Disorders study (Jablensky 
et al., 2000) was undertaken in 1997, and the Survey of High Impact Psychosis (Morgan et al., 2012, 
Morgan et al., 2014) was undertaken in 2010.  Both studies were based on two-phase surveys. 
Firstly, catchment areas were defined and known sites of service contact for those with psychosis 
were enlisted (e.g. hospital, community clinics, primary care physicians, private psychiatrists, non-
government organizations). The first phase involved a census month where all contacts with the 
selected services were screened with a simple check list (Castle et al., 1997) in order to identify 
those with probable psychosis. The second phase involved re-contacting individuals from the census 
survey who were screened-positive for a psychotic disorder (and a set of screen-negative individuals 
in order to define sensitivity and specificity) for a detailed diagnostic interview (Castle et al., 2006) 
and an assessment of other key areas. In the more recent 2010 study, the second-stage interview 
focused strongly on issues of concern for the Australian government such as (a) comorbid physical 
illness, (b) contact with services and types of treatment received, (c) met and unmet needs, (d) 
employment and measures related to social inclusion. Participants were also invited to provide 
blood for measures related to diabetes and metabolic syndrome. A separate consent was used to 
collect and store DNA for future (unspecified) genetic studies. Both studies were designed and 
conducted by clinical researchers, which maximized service participation and investigator 
commitment.  
Canada 
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A Federal initiative, the Canadian Community Health Survey (CCHS), is a biennial household survey 
providing population health estimates representative at the provincial, regional and national level. 
The CCHS, for which data collection began in 2000, consists of two cross-sectional surveys conducted 
over a two-year, repeating cycle. The first survey is designed to collect data from a sample large 
enough to provide information by health region. The second survey focuses on a specific health 
topic, and provides data at the provincial level (Béland, 2002). Mental health and wellbeing was the 
health focus of the 2002 (Gravel and Béland, 2005) and 2012 (not published at the time of writing) 
provincial surveys. The surveys utilized a modified version of the CIDI and provide estimates of 
bipolar disorder at the regional and national level. Schizophrenia was not included in the CCHS due 
to challenges with measurement.  
The mental health and wellbeing CCHS survey targets individuals aged 15 or older who are living in 
private dwellings in the 10 Canadian provinces. The 2002 CCHS used the area frame designed for the 
Canadian Labour Force Survey as its primary sampling frame and set a sample size of 48,000. A 
multistage stratified cluster design is used to sample dwellings within the area frame with 
oversampling of youths aged 15-24. People living on Indian reserves or Crown lands, residents of 
institutions, full-time members of the Canadian Armed Forces, and residents of certain remote 
regions are excluded (Béland, 2002). 
 
China 
China has produced an impressive number of epidemiological surveys covering a range of mental 
disorders including schizophrenia and bipolar disorder. The majority of these population surveys 
have been at the provincial levels (Xiang et al., 2008, Xiaoyong et al., 2004, Wei et al., 2011, Ran et 
al., 2003); however, two significant psychiatric epidemiological surveys have been independently 
undertaken providing nationally representative prevalence estimates for schizophrenia and bipolar 
disorder. The first was in 1993 (Weixi et al., 1998) and the second in  the period of 2001-2005 
(Phillips et al., 2009). Both were household surveys and included participants over 15 years of age 
and 18 years of age, respectively.  
 
The 1993 survey utilized the Chinese Classification of Mental Disorders (CCMD) which is similar in 
structure and categorisation to the ICD and DSM. The 2001-2005 survey conducted a vigorous 2-
stepped diagnostic assessment by utilizing the 12-item General Health Questionnaire as a screener 
on a sample of over 66,000 participants followed by the psychiatrist-administered SCID on all those 
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with identified risk of a disorder. This approach, although more resource-intensive, has several major 
benefits including the inclusion of Psychosis ‘not otherwise specified’ category and the ability of 
skilled interviewers to rephrase standard SCID questions about symptoms if respondents were 
uncertain about the meaning of the initial question (which can happen when respondents with 
different educational levels and language skills are interviewed). In fact, prevalence estimates in this 
study by Phillips band colleagues were substantially higher than those reported in other studies 
done in China from 1982 to 2004 in which different methods were used.  
 
United Kingdom 
The National Psychiatric Morbidity Survey was a household survey representative nationally, with 
the exception of the Highlands and Islands of Scotland (Jenkins et al., 1997a, Jenkins et al., 1997b). 
Nearly 13,000 adults aged 16-65 were selected for interview. Psychiatric assessment was carried out 
by lay interviewers using the Revised Clinical Interview Schedule (CIS-R) (Lewis et al., 1992). 
Measurement of psychosis was distinct whereby all subjects were additionally screened for 
psychosis using the Psychosis Screening Questionnaire (Bebbington and Nayani, 1995), and screen-
positive individuals were examined by psychiatrists using SCAN (Wing et al., 1990). Seven hundred 
and forty-nine subjects were positive on the psychosis screen. Of these, 473 were successfully 
interviewed by psychiatric registrars using SCAN, that is, 63% of those who were positive on the 
psychosis screen.  
Netherlands 
The Netherlands Mental Health Survey and Incidence Study, or NEMESIS, was a large prospective 
cohort study that has been conducted (Bijl et al., 1998a, Bijl et al., 1998b). The first phase was a 
cross-sectional, multistage household survey in 1996 which interviewed over 7,000 participants from 
the general Dutch population aged between 18 and 64 using the CIDI. Those with psychotic 
experiences were followed up with a telephone interview with an experienced clinician (van Nierop 
et al., 2012). Follow-up measurements in the same sample were conducted twice at 12 and 36 
months facilitating the estimation of disorder incidence. Noteworthy were the additional measures 
included in the survey which included subthreshold presentations of symptoms that were 
considered potentially clinically relevant but that fail to satisfy the DSM criteria for a disorder; the 
consequences of mental disorders in terms of care use and care needs; quality of life and functional 
impairments; and determinants of the emergence and the course of mental disorders.  A second 
study has also commenced (NEMESIS 2) (de Graaf et al., 2010), with the baseline study (n = 6646) 
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sample followed up with two additional waves of interview (at three year intervals). DNA has been 
collected from saliva in 76.4% of the baseline sample.  
 
 
Conclusions 
Psychotic and bipolar disorders are associated with persistent symptoms, high levels of disability, 
premature mortality, high health care costs, need for long-term community support, impaired  social 
functioning and low employment rates. A recent study estimated the economic burden of 
schizophrenia in the US at $155.7 billion for 2013, of which  24% were excess direct health care costs 
($37.7 billion), 6% direct non–health care costs ($9.3 billion) and 76% indirect costs ($117.3 billion) 
compared to individuals without schizophrenia. The largest components were excess costs 
associated with unemployment (38%), productivity loss due to caregiving (34%), and direct health 
care costs (24%) (Cloutier et al., 2016).   
Information to quantify the size, distribution, functional impairment and service utilization of 
individuals with these disorders provides important information for health and social service policy 
and planning. The following should be considered in planning surveys to collect this information: 
1. Collect information on symptoms that allow disorders to be measured on a range of 
diagnostic, symptom-level and clinical-stage related criteria.  
2. Collect information on disability and functional impairment and access to services that assist 
individuals to maximize their quality of life.  
3. Collect information on comorbid medical disorders and the extent of access to healthcare 
for those disorders.  
4. Include consumer and, where possible, caregiver perspectives in additional to symptom, 
disability and service utilization.   
5. Using existing data where possible (state and federal registers and health networks).  
6. Use innovative methods, including current and emerging social media and communication 
technology, cross-sectional surveys to identify cohorts for longitudinal follow-up to gain 
information on the course of illness, including remission and relapse.  
7. Incorporate safeguards that respond to the ethical and consent issues necessary to allow 
biological samples (e.g. metabolic and genetic information) to be collected; information 
which has the potential to enhance treatment outcomes and help deliver on the potential 
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identified in the Precision Medicine Initiative (PMI) Cohort Program whose target groups 
include bipolar disorder and schizophrenia. 
 
The United States regularly collects epidemiologic and related information, including from high 
quality surveys, about most of the major contributors to the burden of disease (e.g. cancer, 
cardiovascular disease and substance use disorders) and has world class psychiatric 
epidemiology expertise and experience. The US is ideally placed to be able to assemble and 
analyze the necessary information about psychotic and bipolar disorders to improve health and 
social outcomes for individuals with these conditions.    
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